Liraglutide

Victoza · Saxenda · NN2211 · Daily GLP-1 Analogue

"The GLP-1 analogue that proved the class. Daily injection, 97% homology with human GLP-1, ~13-hour half-life, two FDA approvals (type 2 diabetes as Victoza 2010; obesity as Saxenda 2014). The LEADER cardiovascular outcomes trial established GLP-1 agonists as cardioprotective agents, not just glucose-lowering drugs. The clinical foundation on which semaglutide and tirzepatide were built."

Type

Modified GLP-1 · 97% human homology

Half-life

~13 hours · once-daily SubQ

Status

UK: prescription only medicine (Victoza, Saxenda) · WADA: not specifically listed · US FDA: approved 2010 (T2D), 2014 (obesity) · MHRA-licensed

LEADER trial

13% CV event reduction · landmark trial

Protocol summary

Saxenda dose

0.6 → 3.0 mg/day SubQ

Victoza dose

0.6 → 1.8 mg/day SubQ

Titration

Weekly +0.6 mg over 5 weeks

Clinical-labelled

Saxenda (obesity): 0.6 → 3.0 mg/day · Victoza (T2D): 0.6 → 1.8 mg/day · daily SubQ

If missed >72 hours, restart at 0.6 mg and re-titrate; UK access via NHS or licensed private prescriber

How we read the evidence

FDA-approved as Saxenda (obesity) and Victoza (T2D) · daily injection · superseded by semaglutide and tirzepatide for weight loss but still clinically valid · titration is essential for tolerance

Animal evidence

First-generation GLP-1 receptor agonist with extensive preclinical foundation. Liraglutide is structurally similar to native GLP-1 with modifications (Arg34Lys substitution + C-16 fatty acid attachment via glutamic acid spacer at Lys26) that extend half-life from minutes to ~13 hours and enable once-daily dosing. Animal studies established the dose-response, the appetite-suppression mechanism via hypothalamic GLP-1 receptors, the gastric-emptying delay, the β-cell preservation, and the cardiovascular signal that later shaped LEADER trial design.

Community & clinical practice

Both formulations follow the same titration principle: start at 0.6 mg/day and increase by 0.6 mg weekly over 5 weeks to the maintenance dose — 3.0 mg/day for Saxenda (obesity), 1.8 mg/day for Victoza (T2D). Titration is for GI tolerance, not efficacy — going slower or pausing escalation if nausea/vomiting is significant prevents discontinuation. If a dose is missed for >72 hours, restart at 0.6 mg and re-titrate. Daily SubQ injection (abdomen, thigh, or upper arm), site rotation. Long-term use is the norm — discontinuation typically causes weight regain. In real-world clinical practice (Wilmington et al. 2023 NHS bariatric pre-surgery cohort), Saxenda 3 mg produced consistent weight, BMI, and HbA1c reductions across 6/12/26/52 weeks.

Human trial data

Substantial Phase 3 evidence base. SCALE programme — three 56-week randomised double-blind placebo-controlled trials supporting Saxenda's 2014 FDA approval (NCT01272219, NCT01272232 and others). LEADER trial (N=9,340 T2D patients with high CV risk, 3.8-year median follow-up) demonstrated cardiovascular benefit for liraglutide 1.8 mg vs placebo. SCALE Kids trial in children aged 6–12 (NCT04775082) and 56-week adolescent study extended evidence to paediatric obesity. Approval predicates: an obese-adult titrated-to-3-mg group lost ~5–8% body weight on average — clinically meaningful, but smaller than what semaglutide 2.4 mg or tirzepatide produces in head-to-head comparisons.

Regulatory status

FDA-approved as Victoza (1.8 mg, T2D, 2010) and Saxenda (3.0 mg, weight management, 2014). EMA and MHRA approved across both indications. Boxed warning: risk of thyroid C-cell tumours (based on rodent data; human relevance uncertain) — contraindicated in personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. Other warnings: pancreatitis, gallbladder disease, hypoglycaemia (when combined with insulin or sulfonylureas), acute kidney injury secondary to dehydration from GI side effects. Compounded versions also exist; quality varies. WADA does not list liraglutide.

Convergence

Liraglutide is one of the most clinically validated peptides on the platform — FDA-approved across two indications, decades of trial and registry data, well-defined titration protocol. However, for weight loss specifically, semaglutide and tirzepatide produce substantially larger effect sizes in head-to-head comparisons; liraglutide's main remaining advantages are daily dosing flexibility and longer post-marketing safety record. Standard protocol: 0.6 mg → 3.0 mg over 5 weeks for weight, 0.6 → 1.8 mg for T2D, daily SubQ, long-term use. Pep IQ flags this honestly: legitimate, well-evidenced, but second-line for weight loss vs the newer agents — daily injection is the friction point most users want to avoid.

Origin & Background

The trial that proved GLP-1 drugs protect the heart

Liraglutide is a GLP-1 receptor agonist with 97% amino acid sequence homology to human GLP-1, modified with a C16 fatty acid chain (via a glutamate linker) that enables albumin binding and extends half-life from GLP-1''s ~2 minutes to approximately 13 hours. This pharmacokinetic engineering enabled once-daily dosing -- the innovation that launched the modern GLP-1 drug class.

Developed by Novo Nordisk, liraglutide received FDA approval as Victoza for type 2 diabetes in 2010 (1.2mg and 1.8mg doses), then as Saxenda for chronic weight management in 2014 (3mg dose). These approvals preceded semaglutide by 7 years and provided the clinical foundation -- trial methodology, regulatory precedents, safety characterisation -- on which semaglutide, tirzepatide, and all subsequent GLP-1 drugs were built.

The most scientifically important liraglutide contribution is the LEADER trial (2016) -- a landmark 9341-patient cardiovascular outcomes trial that demonstrated liraglutide significantly reduced major adverse cardiovascular events (MACE) by 13% compared to placebo in T2D patients with high CV risk. This was the first definitive proof that a GLP-1 agonist was cardioprotective, transforming the class from glucose-lowering drugs into cardiovascular medicines. The LEADER results drove an entire generation of cardiovascular outcomes trials across the GLP-1 class and established the scientific basis for prescribing GLP-1 agonists in patients with T2D and established CV disease.

Why liraglutide matters despite being superseded: In raw weight loss (5-8% vs 15% for semaglutide), liraglutide is clearly less effective than newer agents. But it occupies a unique position in the history and science of GLP-1 medicine: it has the longest post-marketing safety record, the most established cardiovascular data, the most paediatric data (approved for obesity in adolescents 12+ years), and provides an important comparative baseline for understanding the class as a whole.

Science & Mechanism

GLP-1R agonism -- the mechanism the whole class shares

Mechanism of Action

GLP-1 receptor activation: Liraglutide binds GLP-1R with high affinity, activating the same Gs-coupled adenylyl cyclase --> cAMP --> PKA pathway as endogenous GLP-1. This produces glucose-dependent insulin secretion (only when glucose is elevated -- the key safety feature preventing hypoglycaemia), glucagon suppression, delayed gastric emptying, and central appetite suppression via hypothalamic GLP-1R.

Albumin binding -- 13-hour half-life: The C16 fatty acid chain enables non-covalent binding to serum albumin (present at high concentration in blood). This albumin-binding dramatically reduces renal clearance and proteolytic degradation, extending half-life from 2 minutes (native GLP-1) to 13 hours (liraglutide). Approximately 99% of liraglutide in circulation is albumin-bound.

Cardioprotection beyond glucose lowering: LEADER and subsequent mechanistic studies showed that liraglutide''s cardiovascular benefits are not fully explained by glycaemic improvement. Direct GLP-1R activation in cardiac tissue and endothelium reduces inflammation, improves endothelial function, reduces visceral fat (a key CV risk driver), and has anti-atherosclerotic effects. These direct mechanisms operate independently of the glycaemic effect.

Weight loss mechanism -- central and peripheral: GLP-1R in the hypothalamus (particularly the arcuate nucleus) suppresses appetite via reduction of NPY/AgRP neuron activity and activation of POMC neurons. Delayed gastric emptying extends satiety after meals. The combination produces spontaneous caloric reduction without requiring conscious dietary restriction.

Renal protection: LEADER also showed a 22% reduction in nephropathy progression. Subsequent data confirmed GLP-1 agonists have direct renoprotective effects via reduction of glomerular hypertension, oxidative stress, and inflammation in the kidney -- extending the indication beyond glycaemia and CV disease to chronic kidney disease protection.

LEADER trial key data (9341 patients, median 3.8 years follow-up): Primary MACE endpoint (CV death, non-fatal MI, non-fatal stroke) reduced 13% vs placebo (HR 0.87, p=0.01). CV death reduced 22%. Renal composite endpoint reduced 22%. HbA1c reduced by ~1.0% at 36 months. Body weight reduced ~2.3kg. The LEADER data is arguably the most important clinical finding in the history of GLP-1 pharmacology -- not because of efficacy magnitude, but because it definitively established the cardiovascular protection mechanism that the entire class now claims.

Benefits & Evidence

What the data shows

❤️

Cardiovascular protection -- LEADER trial

13% MACE reduction, 22% CV death reduction in T2D patients with established CV disease. The most important cardiovascular outcomes data in GLP-1 pharmacology. Established the class as cardioprotective, not merely glucose-lowering.

⬤ Strong -- landmark Phase 3/4 RCT

⚖️

Type 2 diabetes glycaemic control

HbA1c reduction ~1.0-1.5% at therapeutic doses. FDA-approved for T2D as Victoza (1.2mg, 1.8mg). Established efficacy with 15+ years of real-world data.

⬤ Strong -- FDA-approved with extensive RCT data

⚖️

Obesity / weight management

SCALE trial: 5.4kg weight loss vs 0.5kg placebo at 56 weeks (3mg). Approved as Saxenda. Less effective than semaglutide (~5-8% vs 15%) and tirzepatide, but established the obesity indication for the class.

⬤ Strong -- FDA-approved with Phase 3 data

🥖

Renal protection

LEADER: 22% reduction in nephropathy progression. Renal protection data now extends across the GLP-1 class; liraglutide was among the first to demonstrate it in an outcomes trial.

⬤ Strong -- LEADER outcomes data

Things to know

Safety -- 15 years of real-world data

Moderate

GI adverse events -- nausea, vomiting, diarrhoea, constipation. Most common during dose titration. Typically resolve after 4-8 weeks. Titrating slowly (0.6mg --> 1.2mg --> 1.8mg --> 2.4mg --> 3mg over 5 weeks) substantially reduces GI burden.

Mild

Injection site reactions -- redness, bruising at daily injection sites. Rotate sites. Less significant than with weekly preparations given smaller volume per injection.

Moderate

Thyroid C-cell monitoring -- GLP-1R agonists caused thyroid C-cell tumours in rodents. No increase in human thyroid cancer has been observed in 15 years of pharmacovigilance, but the class warning persists. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.